-
公开(公告)号：US12097197B2
公开(公告)日：2024-09-24
申请号：US18069204
申请日：2022-12-20
申请人： Slayback Pharma LLC
发明人： Ashish Anilrao Dubewar , Rahul Dhulaji Bhise , Mahadeo Vasant Mahadik , Shanker Mamidi , Mayur Anshiram Adhav , Raghavender Rao Kategher , Nagaraj Gangam , Sumitra Ashokkumar Pillai , Praveen Kumar Subbappa
IPC分类号： A61K31/497 , A61K9/00 , A61K31/473
CPC分类号： A61K31/497 , A61K9/0019 , A61K31/473
摘要： The present invention relates to stable liquid compositions suitable for parenteral administration in the form of a solution comprising:
(a) netupitant and optionally palonosetron;
(b) at least one pharmaceutically acceptable stabilizer;
(c) at least one pharmaceutically acceptable solubilizer; and
(d) at least one pharmaceutically acceptable vehicle,
wherein netupitant is present at a concentration of about 0.5 mg/mL to about 20 mg/mL and the solution has a pH of about 2 to about 6.
The compositions are suitable for subcutaneous, intravenous, or intramuscular administration. The invention further relates to methods for manufacturing the compositions and methods of using such compositions for prevention, treatment or management of nausea and vomiting.-
公开(公告)号：US20230190737A1
公开(公告)日：2023-06-22
申请号：US18069204
申请日：2022-12-20
申请人： Slayback Pharma LLC
发明人： Ashish Anilrao Dubewar , Rahul Dhulaji Bhise , Mahadeo Vasant Mahadik , Shanker Mamidi , Mayur Anshiram Adhav , Raghavender Rao Kategher , Nagaraj Gangam , Sumitra Ashokkumar Pillai , Praveen Kumar Subbappa
IPC分类号： A61K31/497 , A61K9/00 , A61K31/473
CPC分类号： A61K31/497 , A61K9/0019 , A61K31/473
摘要： The present invention relates to stable liquid compositions suitable for parenteral administration in the form of a solution comprising:
(a) netupitant and optionally palonosetron;
(b) at least one pharmaceutically acceptable stabilizer;
(c) at least one pharmaceutically acceptable solubilizer; and
(d) at least one pharmaceutically acceptable vehicle,
wherein netupitant is present at a concentration of about 0.5 mg/mL to about 20 mg/mL and the solution has a pH of about 2 to about 6.
The compositions are suitable for subcutaneous, intravenous, or intramuscular administration. The invention further relates to methods for manufacturing the compositions and methods of using such compositions for prevention, treatment or management of nausea and vomiting.-
3.发明授权公开(公告)号：US11938217B2
公开(公告)日：2024-03-26
申请号：US18098505
申请日：2023-01-18
申请人： SLAYBACK PHARMA LLC
发明人： Rahul Dhulaji Bhise , Ajay Kumar Singh , Mahadeo Vasant Mahadik , Ashish Anilrao Dubewar , Molugu Prashanth Reddy
CPC分类号： A61K9/0019 , A61K9/08 , A61K31/27 , A61K31/40 , A61K47/183
摘要： Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.
-
4.发明授权公开(公告)号：US11110054B2
公开(公告)日：2021-09-07
申请号：US16170948
申请日：2018-10-25
申请人： Slayback Pharma LLC
发明人： Rahul Dhulaji Bhise , Ajay Kumar Singh , Mahadeo Vasant Mahadik , Ashish Anilrao Dubewar , Molugu Prashanth Reddy
摘要： The present invention provides stable, ready-to-use injectable pharmaceutical compositions, comprising the combination of neostigmine, glycopyrrolate, a stabilizing amount of one or more aminopolycarboxylic acids, and a pharmaceutically acceptable liquid vehicle. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, ethylenediaminetetraacetic acid (EDTA) and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.
-
公开(公告)号：US20240156829A1
公开(公告)日：2024-05-16
申请号：US18487330
申请日：2023-10-16
申请人： Slayback Pharma LLC
发明人： Ashish Anilrao Dubewar , Rahul Dhutaji Bhise , Shanker Mamidi , Mahadeo Vasant Mahadik , Sumitra Ashokkumar Pillai , Satheesh Balasubramanian , Kumar Swamy Ummiti , Mayur Anshiram Adhav , Praveen Kumar Subbappa
CPC分类号： A61K31/5377 , A61K9/0019 , A61K9/107 , A61K47/12 , A61K47/26 , A61K47/44
摘要： The present invention relates to stable pharmaceutical compositions for parenteral administration comprising aprepitant. The present invention further relates to a method for manufacturing the composition as well as to the use of these compositions. Also included are stable pharmaceutical compositions for parenteral administration comprising aprepitant and palonosetron. The pharmaceutical compositions are stable oil-in-water emulsions for parenteral administration and are particularly useful for the prevention and control of acute and delayed chemotherapy-induced nausea and vomiting (CINV), for the prevention of postoperative nausea and vomiting (PONV), and/or for the prevention of radiation induced nausea and vomiting (RINV).
-
6.发明授权公开(公告)号：US10456354B1
公开(公告)日：2019-10-29
申请号：US16176866
申请日：2018-10-31
申请人： Slayback Pharma LLC
发明人： Rahul Dhulaji Bhise , Ajay Kumar Singh , Mahadeo Vasant Mahadik , Ashish Anilrao Dubewar , Molugu Prashanth Reddy
摘要： The present invention provides stable, ready-to-use injectable pharmaceutical compositions, comprising the combination of neostigmine, glycopyrrolate, a stabilizing amount of one or more aminopolycarboxylic acids, and a pharmaceutically acceptable liquid vehicle. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, ethylenediaminetetraacetic acid (EDTA) and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.012 秒)
